Table 3 Prevalence of daily diary-reported symptoms, medication use, and mean (SD) of peak expiratory flow in the study population (n = 37) during the three study waves
Wave 1 (1068 observations) | Wave 2 (1066 observations) | Wave 3 (978 observations) | Total (3112 observations) | |
|---|---|---|---|---|
Symptoms a | n (%) | n (%) | n (%) | n (%) |
Eye irritation/rhinitis | 649 (60.9%) | 68 (6.4%) | 368 (37.7%) | 851 (27.5%) |
Dyspnea | 252 (23.8%) | 112 (10.6%) | 215 (22.9%) | 579 (19.0%) |
Dry cough | 296 (27.9%) | 239 (22.7%) | 272 (28.9%) | 807 (26.4%) |
Allergy medication a | 547 (51.3%) | 118 (11.2%) | 581 (61.9%) | 1246 (40.7%) |
Bronchodilating medication | ||||
No | 389 (36.5%) | 474 (44.9%) | 355 (37.6%) | 1218 (39.7%) |
Less | 46 (4.3%) | 64 (6.1%) | 14 (1.5%) | 124 (4.0%) |
Normal | 533 (50.0%) | 455 (43.1%) | 454 (48.1%) | 1442 (47.0%) |
More | 98 (9.2%) | 62 (5.9%) | 121 (12.8%) | 281 (9.2%) |
Peak expiratory flow (PEF) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
PEFmo (mL) | 434 (81) | 441 (90) | 434 (93) | 436 (88) |
PEFev (mL) | 442 (85) | 448 (93) | 442 (97) | 444 (92) |